Catalent raises $650mm in preferred stock financing to fund Paragon acquisition
- Drug Discovery Tools
- Large Molecule
- Synthesis Technologies, Production Processes
- Contract Research, Toxicology Testing-CRO
- Controlled Release
- OTC, Consumer
- Drug Delivery
- Private Placement
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.